With the consequences of FCPA noncompliance ranging from “huge” to “catastrophic,” compliance should be top-of-mind for U.S. companies doing business with third-party intermediaries and subsidiaries overseas. In a conversation with Mimesis Law’s Lee Pacchia, Foley Partner David Simon discusses how companies should approach investigations to go beyond the “who,” “what,” “where,” and “when” to address the “why,” while 1) meeting U.S. government expectations for the investigation, 2) maintaining control of the investigation, and 3) reining in “scope creep.”
Author(s)
Related Insights
21 October 2024
Events
Legal Overview of the BIOSECURE Act
Foley special counsel John Strom is speaking in the Association for Accessible Medicine’s GRx+Biosims 2024 conference in a panel titled “Legal Overview of the BIOSECURE Act” on October 21.
04 October 2024
Innovative Technology Insights
Decoding California’s Recent Flurry of AI Laws
Governor Newsom signed over 18 AI-related bills into law during September, impacting numerous industries.
17 October 2024
Events
Top Compliance Considerations when Commercializing in the U.S.
Kyle Faget and Nathan "Nate" Beaver, co-chair of Foley's Medical Device and Equipment Area of Focus within the firm's Health Care & Life Sciences Sector, invite you to join us for a webinar on the compliance considerations you need to know when you are commercializing your medical device products in the U.S.